Through our use case for T-ALL, we show that Cascade can help to address this need and while the potential hypotheses generated (NOTCH3 activation being linked to NOTCH1 /CDKN2A loss, alternative activation of FLT3 along with a potential role for alternative splicing of MAML members in NOTCH1 wt patients) would require experimental validation, the goal of Cascade is simply to allow users to rapidly generate novel hypotheses based on their data. The gene discussed is CDKN2A; the disease is acute lymphoblastic leukemia.